BioNTech SE
BioNTech SE is a biotechnology company focused on mRNA-based immunotherapies, with its dominant political signal being $1.78B in disclosed physician payments over four years, while showing zero federal contracts, lobbying spend, or corporate insider buys.
BusinessWhat BNTX does
BioNTech is a German biotechnology company that develops and commercializes mRNA-based therapeutics and vaccines, most notably its COVID-19 vaccine developed in partnership with Pfizer. Its revenue is heavily concentrated in vaccine sales, with a pipeline targeting oncology and infectious diseases. The company's financials are characterized by high revenue volatility tied to pandemic-related demand cycles.
6 months past · 3 months futureBNTX activity timeline
Lifetime Government AwardsBNTX federal contracts
BNTX doesn't hold direct federal contracts.
Verified via USASpending.gov: $0 reported in direct prime-contract awards. Companies in this position typically sell federal services indirectly through prime contractors and integrators (e.g., Lockheed Martin, Booz Allen, Microsoft Azure) or through commercial channels that don't appear in USASpending data.
Smart Money · 13F HoldingsHedge funds holding BNTX
Politicians Trading BNTXMembers of Congress with recent BNTX positions
Congressional TradesWho in Congress is trading BNTX
Corporate Insiders · Form 4What CEOs, CFOs, and directors are doing with their own stock
No Form 4 activity recorded in the last 180 days.
Bills Affecting BNTXLive legislation impacting this stock
Political ProfileWhere BNTX sits in Washington
[object Object]
STRUCTURAL: High regulatory density (score 85) from healthcare sector bills and $1.78B in physician payment disclosures (`get_political_influence.doctor_payments`) creates significant oversight risk. EVIDENTIARY: No federal contracts (`get_government_precedent`), zero lobbying spend, zero corporate insider buys in 180 days (`get_corporate_insider_signal`), and only two congressional sale transactions (`Top congressional traders`). Net: High structural regulatory exposure is offset by a complete lack of evidentiary political engagement or financial interest from government or insiders.
Regulatory ExposureThreats & opportunities
Regulatory threats
-
Heightened scrutiny of physician payment disclosures under the Sunshine ActCMS (Centers for Medicare & Medicaid Services)"`get_political_influence.doctor_payments` shows $1.78B in total payments from 2021-2024, creating regulatory and reputational exposure."
Regulatory opportunities
-
Potential for expedited regulatory pathways for oncology mRNA pipelineFDA (Food and Drug Administration)"Recent bill impacts in `Recent bill_impacts` (8 healthcare bills) indicate active legislative focus on the sector, which can create fast-track opportunities."
Live signals + predictions for BNTX — for Founders
The free page above gives you the public record. Members see the real-time intelligence layer on top of it:
- Live 7-layer signal scores when Congress trades BNTX
- Bill Pass Index v2 odds for every bill on the watch list
- Iron Triangle alerts (committee × donor × trade)
- SEC Form 4 cluster detection (CEO + CFO + director buys)
- Whale-Opportunity expected-value ranking
- Custom watchlist alerts via email + Discord